Nur77 modulator 6

Nur77 modulator 6 是一种 Kd 为 0.40 μM 的 Nur77 调节剂,可通过功能性调控 Nur77 诱导结直肠肿瘤细胞发生有丝分裂阻滞和凋亡 (apoptosis),并依赖 Nur77 诱导的有丝分裂阻滞抑制结直肠癌细胞增殖,对结直肠肿瘤细胞具有抗增殖活性,可用于结直肠癌的相关研究。
Nur77 modulator 6
产品编号: MS-L30592 分子式: C20H14ClF3N2 分子量: 374.79
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Nur77 modulator 6 是一种 Kd 为 0.40 μM 的 Nur77 调节剂,可通过功能性调控 Nur77 诱导结直肠肿瘤细胞发生有丝分裂阻滞和凋亡 (apoptosis),并依赖 Nur77 诱导的有丝分裂阻滞抑制结直肠癌细胞增殖,对结直肠肿瘤细胞具有抗增殖活性,可用于结直肠癌的相关研究。

生物实验数据

生物活性 Nur77 modulator 6 is a Nur77 modulator with a Kd of 0.40 μM that functionally regulates Nur77 to induce mitotic arrest and apoptosis in colorectal tumor cells, inhibits colorectal cancer cell proliferation in a Nur77-induced mitotic arrest-dependent manner, exhibits antiproliferative activity against colorectal tumor cells, and can be used for research related to colorectal cancer.
IC50 & Target

Nur77/NR4A1

 

体外研究
(In Vitro)

Nur77 modulator 6 (Compound a6) (0.05-2.07 μM) 可与纯化的 Nur77-LBD 蛋白结合,解离常数为 0.40 μM,其结合亲和力强于 BI1071。
Nur77 modulator 6 (0.25-0.5 μM; 48 h) 可强效抑制 HCT116 细胞和 MC38 细胞的增殖,孵育 48 h 后对两种细胞的 IC50 分别为 0.53 μM 和 0.16 μM,其抗增殖活性强于 BI1071 (MS-Z82640)。
Nur77 modulator 6 (0.125-1.0 μM; 6 h) 可在 HCT116 细胞中诱导剂量依赖性的 G2/M 期有丝分裂阻滞,在 0.25、0.5 和 1.0 μM 浓度下分别有 48.60%、74.37%和 79.62%的细胞发生阻滞,同时上调有丝分裂标志物 p-S10-H3 和 cyclin B1。
Nur77 modulator 6 (0.25-0.5 μM; 6 h) 可在 MC38 细胞中诱导剂量依赖性 G2/M 期有丝分裂阻滞,在 0.25 μM 和 0.5 μM 浓度下分别有 58.86%和 81.78%的细胞发生阻滞,并上调有丝分裂标志物 p-S10-H3 和 cyclin B1。
Nur77 modulator 6 (0.5 μM; 6 h) 可在 HeLa 细胞中诱导依赖于 Nur77 的 G2/M 期有丝分裂阻滞。
Nur77 modulator 6 (0.5 μM; 6-24 h) 可在 HCT116 细胞中诱导有丝分裂依赖性凋亡,经 24 h 处理后,发生有丝分裂阻滞的细胞会逐渐进展为凋亡性细胞死亡。

Cell Proliferation Assay

Cell Line: human HCT116 colorectal carcinoma cells, murine MC38 colon carcinoma cells
Concentration: 0.25 μM, 0.5 μM
Incubation Time: 48 h
Result: Inhibited HCT116 cell proliferation by 33.28% at 0.25 μM.
Inhibited HCT116 cell proliferation by 51.50% at 0.5 μM.
Exhibited an IC50 of 0.53 μM for HCT116 cells and 0.16 μM for MC38 cells, both lower than the IC50 values of BI1071 in these cell lines.

Cell Cycle Analysis

Cell Line: human HCT116 colorectal carcinoma cells
Concentration: 0.125-1.0 μM
Incubation Time: 6 h
Result: Induced G2/M phase arrest in 79.62% of HCT116 cells at 1.0 μM.
Induced G2/M phase arrest in 74.37% of HCT116 cells at 0.5 μM.
Induced G2/M phase arrest in 48.60% of HCT116 cells at 0.25 μM.
Upregulated mitotic markers p-S10-H3 and cyclin B1 in a dose-dependent manner, with significant increases observed at 0.25 μM and 0.5 μM compared to control cells.

Cell Cycle Analysis

Cell Line: murine MC38 colon carcinoma cells
Concentration: 0.25-0.5 μM
Incubation Time: 6 h
Result: Induced G2/M phase arrest in 58.86% of MC38 cells at 0.25 μM.
Induced G2/M phase arrest in 81.78% of MC38 cells at 0.5 μM.
Upregulated mitotic markers p-S10-H3 and cyclin B1, with the 0.5 μM treatment causing a significant increase in p-S10-H3 levels compared to BI1071 at the same concentration.

Cell Cycle Analysis

Cell Line: Nur77-knockdown and control HeLa cells
Concentration: 0.5 μM
Incubation Time: 6 h
Result: Induced G2/M phase arrest in 58.13% of control siRNA-transfected HeLa cells and upregulated p-S10-H3 and cyclin B1.
Reduced the G2/M arrest rate to 34.37% in Nur77-knockdown HeLa cells and significantly suppressed the upregulation of p-S10-H3 and cyclin B1.

Apoptosis Analysis

Cell Line: human HCT116 colorectal carcinoma cells
Concentration: 0.5 μM
Incubation Time: 6 h, 12 h, 24 h
Result: Caused mitotic chromosome disorganization at 6 h.
Induced cleaved caspase-3 staining (indicative of apoptosis) in a substantial number of mitotically arrested cells by 24 h.
Induced mitotic arrest and apoptosis in asynchronous cells, but these effects were abolished in G1/S-synchronized cells, confirming mitosis-dependent cell death.
体内研究
(In Vivo)

Nur77 modulator 6 (Compound a6) (0.125-0.5 μM; 24 h) 在斑马鱼中表现出较低的胚胎毒性,在最高测试剂量 0.5 μM 下的死亡率为 8.9%,显著低于 BI1071 的毒性。

Animal Model: wild-type AB strain (2 hours post-fertilization)
Dosage: 0.125 μM; 0.25 μM; 0.5 μM
Administration: immersion; 24-hour exposure
Result: Exhibited no apparent toxicity at 0.125 μM and 0.25 μM, with no significant difference in mortality compared to the control group.
Caused only 8.9% mortality at 0.5 μM, which was significantly lower than the mortality induced by the reference compound BI1071 at the same concentration (27.8%).

化学信息

分子量 374.79
分子式 C20H14ClF3N2

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础